The 7 major pleural diseases markets reached a value of US$ 2.7 Billion in 2023. Looking forward, the publisher expects the 7MM to reach US$ 4.1 Billion by 2034, exhibiting a growth rate (CAGR) of 4.75% during 2023-2034.
The pleural diseases market has been comprehensively analyzed in this report titled "Pleural Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Pleural diseases refer to a group of medical conditions that affect the pleura, which is the thin membrane that lines the lungs and the inside of the chest cavity. Pleurisy, pleural effusion, and pneumothorax are the three main types of this disorder. Pleurisy is an inflammation of the pleura that often causes sharp chest pain during breathing. Pleural effusion refers to the accumulation of excessive fluid in the space between the two layers of the pleura, whereas pneumothorax is the presence of air or gases in the pleural cavity, which leads to a partial or complete collapse of the lung. The common symptoms include shortness of breath, fatigue, rapid heart rate, coughing, etc. The diagnosis of pleural diseases often involves a combination of medical history evaluation, physical examination, and imaging tests. Blood workups may be performed to check for markers of infection or inflammation that may be contributing to the underlying indications. The healthcare provider may also conduct a thoracoscopy, which helps in visualizing the pleura and ruling out other possible causes among patients.
The rising cases of infections, such as pneumonia and tuberculosis, that can cause inflammation or the accumulation of fluid and pus in the pleural space are primarily driving the pleural diseases market. Besides this, the increasing prevalence of chest trauma, like rib fractures, which can puncture or lacerate the lung tissues and disrupt the normal drainage mechanisms of the pleura, is also propelling the market growth. Additionally, the widespread adoption of various corticosteroids and nonsteroidal anti-inflammatory drugs to reduce inflammation as well as manage symptoms of the ailment is acting as another significant growth-inducing factor. Apart from this, the escalating application of pleurodesis techniques, in which a sclerosing agent is injected into the affected site to create adhesions between the two layers of the pleura, thereby preventing the recurrence of fluid or air accumulation, is also bolstering the market growth. Furthermore, the emerging popularity of video-assisted thoracoscopic surgery on account of its several advantages over traditional open surgeries, such as minimal invasion, shorter hospital stays, reduced postoperative pain, etc., is expected to drive the pleural diseases market in the coming years.
This report provides an exhaustive analysis of the pleural diseases market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for pleural diseases and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the pleural diseases market in any manner.
The pleural diseases market has been comprehensively analyzed in this report titled "Pleural Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Pleural diseases refer to a group of medical conditions that affect the pleura, which is the thin membrane that lines the lungs and the inside of the chest cavity. Pleurisy, pleural effusion, and pneumothorax are the three main types of this disorder. Pleurisy is an inflammation of the pleura that often causes sharp chest pain during breathing. Pleural effusion refers to the accumulation of excessive fluid in the space between the two layers of the pleura, whereas pneumothorax is the presence of air or gases in the pleural cavity, which leads to a partial or complete collapse of the lung. The common symptoms include shortness of breath, fatigue, rapid heart rate, coughing, etc. The diagnosis of pleural diseases often involves a combination of medical history evaluation, physical examination, and imaging tests. Blood workups may be performed to check for markers of infection or inflammation that may be contributing to the underlying indications. The healthcare provider may also conduct a thoracoscopy, which helps in visualizing the pleura and ruling out other possible causes among patients.
The rising cases of infections, such as pneumonia and tuberculosis, that can cause inflammation or the accumulation of fluid and pus in the pleural space are primarily driving the pleural diseases market. Besides this, the increasing prevalence of chest trauma, like rib fractures, which can puncture or lacerate the lung tissues and disrupt the normal drainage mechanisms of the pleura, is also propelling the market growth. Additionally, the widespread adoption of various corticosteroids and nonsteroidal anti-inflammatory drugs to reduce inflammation as well as manage symptoms of the ailment is acting as another significant growth-inducing factor. Apart from this, the escalating application of pleurodesis techniques, in which a sclerosing agent is injected into the affected site to create adhesions between the two layers of the pleura, thereby preventing the recurrence of fluid or air accumulation, is also bolstering the market growth. Furthermore, the emerging popularity of video-assisted thoracoscopic surgery on account of its several advantages over traditional open surgeries, such as minimal invasion, shorter hospital stays, reduced postoperative pain, etc., is expected to drive the pleural diseases market in the coming years.
This report provides an exhaustive analysis of the pleural diseases market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for pleural diseases and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the pleural diseases market in any manner.
Time Period of the Study
- Base Year: 2023
- Historical Period: 2018-2023
- Market Forecast: 2024-2034
Countries Covered
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the pleural diseases market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the pleural diseases market
Competitive Landscape:
This report also provides a detailed analysis of the current pleural diseases marketed drugs and late-stage pipeline drugs.In-Market Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
- How has the pleural diseases market performed so far and how will it perform in the coming years?
- What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
- What was the country-wise size of the pleural diseases market across the seven major markets in 2023 and what will it look like in 2034?
- What is the growth rate of the pleural diseases market across the seven major markets and what will be the expected growth over the next ten years?
- What are the key unmet needs in the market?
Epidemiology Insights
- What is the number of prevalent cases (2018-2034) of pleural diseases across the seven major markets?
- What is the number of prevalent cases (2018-2034) of pleural diseases by age across the seven major markets?
- What is the number of prevalent cases (2018-2034) of pleural diseases by gender across the seven major markets?
- How many patients are diagnosed (2018-2034) with pleural diseases across the seven major markets?
- What is the size of the pleural diseases patient pool (2018-2023) across the seven major markets?
- What would be the forecasted patient pool (2024-2034) across the seven major markets?
- What are the key factors driving the epidemiological trend of pleural diseases?
- What will be the growth rate of patients across the seven major markets?
Pleural Diseases: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
- What are the current marketed drugs and what are their market performance?
- What are the key pipeline drugs and how are they expected to perform in the coming years?
- How safe are the current marketed drugs and what are their efficacies?
- How safe are the late-stage pipeline drugs and what are their efficacies?
- What are the current treatment guidelines for pleural diseases drugs across the seven major markets?
- Who are the key companies in the market and what are their market shares?
- What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the pleural diseases market?
- What are the key regulatory events related to the pleural diseases market?
- What is the structure of clinical trial landscape by status related to the pleural diseases market?
- What is the structure of clinical trial landscape by phase related to the pleural diseases market?
- What is the structure of clinical trial landscape by route of administration related to the pleural diseases market?
Table of Contents
?1 Preface3 Executive Summary6 Patient Journey9 Pleural Diseases - Unmet Needs10 Pleural Diseases - Key Endpoints of Treatment13. Pleural Diseases - Attribute Analysis of Key Marketed and Pipeline Drugs16 Pleural Diseases - Recent Events and Inputs From Key Opinion Leaders18 Pleural Diseases Market - Strategic Recommendations19 Appendix
2 Scope and Methodology
4 Pleural Diseases - Introduction
5 Pleural Diseases - Disease Overview
7 Pleural Diseases - Epidemiology and Patient Population
8 Pleural Diseases - Treatment Algorithm, Guidelines, and Medical Practices
11 Pleural Diseases - Marketed Products
12 Pleural Diseases - Pipeline Drugs
14. Pleural Diseases - Clinical Trial Landscape
15 Pleural Diseases - Market Scenario
17 Pleural Diseases Market - SWOT Analysis
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 130 |
| Published | May 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 2.7 Billion |
| Forecasted Market Value ( USD | $ 4.1 Billion |
| Compound Annual Growth Rate | 3.9% |
| Regions Covered | Global |
